PURPOSE: We previously reported the efficacy of zoledronic acid 4 mg versus placebo (every 3 weeks for 24 months) for the prevention of skeletal-related events (SREs) in men with advanced prostate cancer and bone metastases. We conducted several retrospective exploratory analyses to determine whether zoledronic acid has continuing efficacy during long-term treatment. PATIENTS AND METHODS: This report included analysis of the occurrence of SREs during the extension phase only (months 16-24), analysis of skeletal complications excluding the first SRE at 15 months (core phase), and stratified analysis of patients by history of SREs before study entry. RESULTS:Patients (N=422) were randomized to receive zoledronic acid 4 mg or placebo. For the 132 patients who entered the extension phase, zoledronic acid significantly delayed the onset of first SRE (P=.009) and decreased the risk of developing an SRE by 53% compared with placebo (P=.022). Among all 422 patients, zoledronic acid significantly reduced the incidence of a second on-study SRE (P=.017) and significantly delayed the median time to second SRE compared with placebo (P=.006) at 15 months. Among 144 patients (34%) with a history of SREs before study entry, zoledronic acid significantly reduced the skeletal morbidity rate by 65% (P=.036) and reduced the overall risk of developing an SRE by 40% (P=.028) compared with placebo at 24 months. CONCLUSION: This analysis confirms our previously reported results and suggests that long-term treatment with zoledronic acid provides continuing clinical benefit in patients with advanced prostate cancer, even after the occurrence of SREs.
RCT Entities:
PURPOSE: We previously reported the efficacy of zoledronic acid 4 mg versus placebo (every 3 weeks for 24 months) for the prevention of skeletal-related events (SREs) in men with advanced prostate cancer and bone metastases. We conducted several retrospective exploratory analyses to determine whether zoledronic acid has continuing efficacy during long-term treatment. PATIENTS AND METHODS: This report included analysis of the occurrence of SREs during the extension phase only (months 16-24), analysis of skeletal complications excluding the first SRE at 15 months (core phase), and stratified analysis of patients by history of SREs before study entry. RESULTS:Patients (N=422) were randomized to receive zoledronic acid 4 mg or placebo. For the 132 patients who entered the extension phase, zoledronic acid significantly delayed the onset of first SRE (P=.009) and decreased the risk of developing an SRE by 53% compared with placebo (P=.022). Among all 422 patients, zoledronic acid significantly reduced the incidence of a second on-study SRE (P=.017) and significantly delayed the median time to second SRE compared with placebo (P=.006) at 15 months. Among 144 patients (34%) with a history of SREs before study entry, zoledronic acid significantly reduced the skeletal morbidity rate by 65% (P=.036) and reduced the overall risk of developing an SRE by 40% (P=.028) compared with placebo at 24 months. CONCLUSION: This analysis confirms our previously reported results and suggests that long-term treatment with zoledronic acid provides continuing clinical benefit in patients with advanced prostate cancer, even after the occurrence of SREs.
Authors: Donald L Patrick; Charles S Cleeland; Roger von Moos; Lesley Fallowfield; Rachel Wei; Katarina Öhrling; Yi Qian Journal: Support Care Cancer Date: 2014-12-23 Impact factor: 3.603
Authors: Evan Y Yu; Christophe Massard; Mitchell E Gross; Michael A Carducci; Stephane Culine; Gary Hudes; Edwin M Posadas; Cora N Sternberg; George Wilding; Géralyn C Trudel; Prashni Paliwal; Karim Fizazi Journal: Urology Date: 2011-05 Impact factor: 2.649
Authors: Fred Saad; Neal Shore; Hendrik Van Poppel; Dana E Rathkopf; Matthew R Smith; Johann S de Bono; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Peter F A Mulders; Paul Mainwaring; John D Hainsworth; Tomasz M Beer; Scott North; Yves Fradet; Thomas A Griffin; Peter De Porre; Anil Londhe; Thian Kheoh; Eric J Small; Howard I Scher; Arturo Molina; Charles J Ryan Journal: Eur Urol Date: 2015-05-16 Impact factor: 20.096
Authors: Bevin C English; Caitlin E Baum; David E Adelberg; Tristan M Sissung; Paul G Kluetz; William L Dahut; Douglas K Price; William D Figg Journal: Ther Clin Risk Manag Date: 2010-11-19 Impact factor: 2.423